Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To evaluate the combined effect of lesion activity and pathologic processes occurring in both chronically demyelinated lesions and normal-appearing white matter (NAWM) on brain atrophy in MS.
Methods Pre- and post-gadolinium T1, fluid attenuation inversion recovery, and diffusion tensor imaging images were acquired from 50 consecutive patients with relapsing-remitting MS (all, but one, on disease-modifying therapy) at baseline and 5 years. Brain atrophy was measured using structural image evaluation, using normalization of atrophy percent brain volume change (PBVC) analysis.
Results During follow-up, brain volume diminished by 2.0% ± 1.1%. PBVC was not associated with patient age, disease duration, sex, or type of treatment. PBVC moderately correlated with baseline lesion load (r = −0.38, p = 0.016), but demonstrated strong association with new lesion activity (r = −0.63, p < 0.001). Brain atrophy was also strongly linked to the increase of water diffusion within chronic MS lesions (r = −0.62, p < 0.001). In normal-appearing white matter (NAWM), PBVC demonstrated a significant correlation with both baseline and longitudinal increase of demyelination as measured by radial diffusivity (RD, r = −0.44, p = 0.005 and r = −0.35, p = 0.026, respectively). Linear regression analysis explained 62% of the variance in PBVC. It confirmed the major role of new lesion activity (p = 0.002, standardized beta-coefficient −0.42), whereas change in diffusivity inside chronic lesions and NAWM RD at baseline also contributed significantly (p = 0.04 and 0.02, standardized beta-coefficient −0.31 and −0.29, respectively), increasing predictive power of the model by 55%.
Conclusion In addition to new lesion activity, progressive loss of demyelinated axons in chronic lesions and the degree of demyelination in NAWM significantly contribute to accelerated loss of brain tissue in patients with MS receiving immunomodulatory therapy.
Glossary
- AD=
- axial diffusivity;
- DTI=
- diffusion tensor imaging;
- EDSS=
- Expanded Disability Status Scale;
- FLAIR=
- fluid attenuation inversion recovery;
- FSL=
- Functional MRI of the Brain Software Library;
- GAD=
- gadolinium;
- MD=
- mean diffusivity;
- NAWM=
- normal-appearing white matter;
- PBVC=
- percent brain volume change;
- RD=
- radial diffusivity;
- ROI=
- region of interest;
- RRMS=
- relapsing-remitting MS
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the NMSS.
- Received November 27, 2018.
- Accepted in final form May 7, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imagingSvetlana Bezukladova, Jouni Tuisku, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, March 02, 2020 -
Article
High serum neurofilament associates with diffuse white matter damage in MSMaija Saraste, Svetlana Bezukladova, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, December 08, 2020 -
Article
Natalizumab in progressive MSResults of an open-label, phase 2A, proof-of-concept trialJeppe Romme Christensen, Rikke Ratzer, Lars Börnsen et al.Neurology, March 28, 2014 -
Article
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H. Miller, Robert J. Fox, J. Theodore Phillips et al.Neurology, February 13, 2015